CONCLUSIONS: Most patients/physicians are comfortable with a non-invasive test(s). Although a 5% error rate seems acceptable to many, a substantial subset feels that 99% or higher negative predictive value is required. Thus, a personalized approach with shared-decision making between patients and physicians is essential to optimize patient care in such situations.
INTRODUCTION AND OBJECTIVES: While serial biopsies are a key component of most active surveillance (AS) programs, surveillance protocols differ as to when the first surveillance biopsy should be performed. Some protocols mandate a confirmatory biopsy while in others, the first surveillance biopsy is performed at 1 year. In the present study we sought to determine differential impact of obtaining the first surveillance biopsy either within 6 months or at 9-15 months after diagnosis.
METHODS: We retrospectively identified patients who enrolled in a prostate cancer active surveillance (AS) program during 2004-2015 and underwent a biopsy either 6 months or between 9-15 months after their initial diagnostic biopsy. Eligibility for enrollment in AS was defined according to MSK criteria (biopsy Gleason: 6; biopsy T stage: cT1c or cT2a, diagnostic PSA <10, % positive for each core 50%, 3 positive cores, or if number of total cores >12, then number of positive cores 25% of the total cores). We compared MSK-defined eligibility for AS in patients who received a second biopsy at either 6 or 9-15 months after their initial diagnostic biopsy.
RESULTS: A total of 115 patients on AS were identified within the study period. 62 (53.9) and 53 (46.1%) of patients underwent a second biopsy at 6 or 9-15 months after their initial diagnostic biopsy, respectively (table) . Age, number of biopsy cores and positive cores, serum PSA, and eligibility for AS by MSK criteria were similar between groups. 56(90.3%) and 42 (79.2%) of patients initially met MSK AS criteria. Of these, those rebiopsied at 9-15 months appear more apt to be reclassified as ineligible than patients rebiopsied at 6 months (42.9 v. 25.0%, p¼0.082). Patients biopsied at 6 months had more cores taken at the second biopsy (15(IQR 12-16) vs. 12 (12-12), p<.001) CONCLUSIONS: Surveillance protocols differ as to when the first surveillance biopsy is performed. In patients initially meeting AS inclusion criteria, a delay in confirmatory biopsy may be associated with a higher rate (42.9% v 25.0%) of AS ineligibility. Just as important, 25% of patients immediately learn they do not meet AS criteria. These findings may be due to disease progression rather than under sampling, as patients who were biopsied at 6 months had more biopsies performed. These data may be helpful in patient counseling prior to AS enrollment. METHODS: Between 2009 and 2016, 235 patients were included to AS program for low risk PCa according to the PRIAS criteria. 95 underwent a mpMRI and represent the study population. Number, size, location and grading of mpMRI lesions were recorded. We compared pathologic outcomes in patients submitted to targeted biopsies. csPCa was defined as Gleason score >6. We analyzed the mpMRI performed in patients on AS and correlated mpMRI findings to histopathological results of subsequent biopsies. The rates of csPCa was assessed in patients submitted to prostate biopsy after mpMRI according to PIRADS score, for the biopsy approach (targeted vs. systematic).
RESULTS: 80 patients underwent more than one mpMRI, resulting in 120 evaluable mpMRI. Median time from protocol entry to mpMRI was 12 months. Overall, 48 (40.0%) and 72 (60.0%) patients had a PIRADS score 2 and 3, respectively. PIRADS score was 3 in 32 (44.4%), 4 in 31 (43.1%), and 5 in 9 (12.5%) patients. Median and mean lesion size at MRI were 9 and 9.1 mm. 34 (35%) suspicious lesions were localized at the transitional zone of the prostate, while 23 (23.7%), 9 (13.5%), and 27 (27.8%) at the apex, the base and the lateral zone. 18 patients (18.9%) had >1 suspicious lesion. Overall, 75 patients underwent a biopsy after mpMRI, 34 (45.4%) with a targeted approach and 41 (54.6%) with random systematic biopsies. Of 75 patients, 54 (72.5%) had PIRADS 3 while the others (n¼21) had PIRADS 2. Of 54 patients with PIRADS 3, 17 (31.4%) had Gleason 7. However, patients with PIRADS 3 submitted to targeted biopsy (n¼34), Gleason 7 or higher was found in 23 (67.6%) vs. 7 (33.3%) in patients with PIRADS score 3 submitted to systematic biopsies (p¼0.001). Of patients submitted to targeted biopsy (n¼34), Gleason 7 outside of the targeted area was found in 7 patients (20.1%). Finally, of 21 patients with PIRADS 2, 7 (33.3%), 11 (52,3%) and 3 (14.5%) had negative biopsy, Gleason 6 and Gleason 7 at systematic biopsy. These figures resulted in 3+7/75 (13%) patients with csPCa that were missed by mpMRI.
CONCLUSIONS: 80% of AS patients submitted to mpMRI have suspicious csPCa, especially in areas not normally investigated by means of random biopsies. Therefore, mpMRI should be taken into account when evaluating candidates for AS. However, 13% of clinically significant cancers may be missed by mpMRI.
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